GlassScriptPhysician profile
Frances Landrum
NPI 1922238260
$4,665.85
in general payments reported to CMS, 2019-2025
31 companies · $827 in 2025
The $827 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $939 · 2023: $1,443 · 2024: $1,456 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $821.18 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $676.90 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $486.51 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $432.65 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.72 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $283.13 | 2022-2023 | |
| Glaxosmithkline, LLC. | $258.49 | 2022-2025 | Arexvy, Shingrix |
| Amgen INC. | $250.35 | 2022-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $136.75 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $112.76 | 2022-2023 | Linzess |
| Novartis Pharmaceuticals Corporation | $96.96 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $86.53 | 2023-2024 | Belsomra, Steglatro, Verquvo |
| Sanofi-Aventis U.S. LLC | $77.47 | 2023-2025 | |
| Corcept Therapeutics | $73.67 | 2025 | Korlym |
| Dexcom, INC. | $71.72 | 2022-2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $61.66 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $51.98 | 2023 | Quviviq |
| Abbott Laboratories | $48.84 | 2023-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $41.11 | 2024 | Yupelri |
| Corium, LLC | $39.68 | 2023 | Adlarity |
| Medtronic, INC. | $37.22 | 2025 | Interstim |
| Janssen Pharmaceuticals, INC | $34.13 | 2022 | |
| Verona Pharma, INC. | $33.66 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $23.42 | 2024 | |
| Astellas Pharma US INC | $21.18 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $17.72 | 2024 | Zoryve |
| Seqirus USA INC | $17.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.61 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.35 | 2024 | Rexulti |
| Nevro Corp. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Landrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.